Tejara Capital Ltd Takes $2.27 Million Position in QuidelOrtho Corporation $QDEL

Tejara Capital Ltd purchased a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 129,890 shares of the company’s stock, valued at approximately $2,275,000. Tejara Capital Ltd owned about 0.19% of QuidelOrtho as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its holdings in QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after acquiring an additional 819,908 shares during the period. BlackRock Inc. bought a new stake in QuidelOrtho in the second quarter valued at about $196,212,000. Invesco Ltd. boosted its holdings in QuidelOrtho by 19.4% during the fourth quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock worth $99,122,000 after buying an additional 563,893 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of QuidelOrtho by 7.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company’s stock valued at $50,085,000 after acquiring an additional 212,481 shares during the last quarter. Finally, State Street Corp increased its stake in shares of QuidelOrtho by 1.3% in the 4th quarter. State Street Corp now owns 2,704,355 shares of the company’s stock valued at $77,236,000 after acquiring an additional 35,616 shares during the last quarter. 99.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on QDEL. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Zacks Research cut shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 12th. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Finally, Citigroup increased their price objective on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Three equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, QuidelOrtho currently has a consensus rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Stock Up 7.6%

QuidelOrtho stock opened at $14.85 on Friday. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho Corporation has a 1-year low of $9.92 and a 1-year high of $35.58. The company has a fifty day simple moving average of $15.81 and a 200 day simple moving average of $16.53. The company has a market cap of $1.02 billion, a P/E ratio of -0.96 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The company had revenue of $630.90 million during the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Research analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.